Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07680946
PHASE2
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Sponsor: TG Therapeutics, Inc.
View on ClinicalTrials.gov
Summary
The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by positive and negative syndrome scale (PANSS) total score in participants with schizophrenia.
Official title: Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-07-06
Completion Date
2029-03-01
Last Updated
2026-07-02
Healthy Volunteers
No
Conditions
Interventions
DRUG
Ublituximab
Administered as an IV infusion.